Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the best performing mid cap stocks so far in 2025. On July 10, Soleno Therapeutics announced that the sales of its new Prader-Willi disease drug, ...

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.

Now, the Bystraks are joining with other Prader-Willi families in Western New York to raise awareness about the condition -- as well as funds for research into the syndrome.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Mixed analysts’ ...

The FDA has approved Skytrofa (lonapegsomatropin-tcgd) for treating adults with growth hormone deficiency (GHD).This ...

Abivax, MapLight Therapeutics, Everest Medicines, and Soleno Therapeutics bagged the biggest biotech funding rounds overall ...

Katie Price has revealed she 'can't wait' to see the effect son Harvey's medication has on him after admitting her eldest ...

Katie Price has shared an update on her eldest son Harvey Price's weight loss journey, admitting she is 'fascinated' to see what he will look like after shedding the pounds ...

Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET today to review its second quarter 2025 financial results and recent business activities ...

We came across a bullish thesis on Harmony Biosciences Holdings, Inc. on In. Specter’s Substack. In this article, we will ...

Instead, they often receive off-label antipsychotics. Investors have also zeroed in on Acadia Pharmaceuticals' ACP-101, a potential treatment for Prader-Willi syndrome, or PWS.

Next month will be the first opportunity to gauge the commercial launch of a new treatment for Prader-Willi syndrome, a rare genetic disease that causes an insatiable desire to eat.